Business
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif., May 13, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025.
About this update from An2 Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/c4f9eca9218ab9a041dc9fed4db7315b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5gPsGre9snBMd8nwyrHhJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c4f9eca9218ab9a041dc9fed4db7315b","width":480,"height":270}},"lazy":false},{"type":"text","content":"Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., May 13, 2025--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025.","length":309,"tagName":"p"},{"type":"text","content":""As we look ahead to the remainder of 2025, we are poised to advance our pipeline leveraging our boron chemistry platform, which has the potential to address serious unmet needs of patients. We have high-impact clinical programs for Chagas disease and melioidosis, enabling data for potential development of epetraborole in NTM lung disease caused by M. abscessus, and an emerging portfolio of oncology programs that includes ENPP1 and PI3Kα for solid tumor indications, where our boron chemistry platform has potential for best-in-class molecules," said Eric Easom, Co-founder, Chairman, President and CEO. "We remain committed to maintaining a disciplined approach to capital allocation, including using non-dilutive funding to leverage our infrastructure and capabilities for generating near and long-term growth for our shareholders with multiple pathways to success."","length":892,"tagName":"p"},{"type":"text","content":"First Quarter & Recent Business Updates:","length":44,"tagName":"p"},{"type":"text","content":"Chagas Disease","length":14,"tagName":"p"},{"type":"text","content":"The Company has initiated start up activities for a Phase 1 first in human clinical study of its product candidate, AN2-502998, which has curative potential for chronic Chagas disease...